Literature DB >> 36063201

Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer.

Alexander Herold1, Christian Wassipaul1, Michael Weber1, Florian Lindenlaub1, Sazan Rasul1, Anton Stift2, Judith Stift3,4, Marius E Mayerhoefer1,5, Marcus Hacker1, Ahmed Ba-Ssalamah1, Alexander R Haug1,6, Dietmar Tamandl7.   

Abstract

PURPOSE: The purpose of this study was to determine whether multiparametric positron emission tomography/magnetic resonance imaging (mpPET/MRI) can improve locoregional staging of rectal cancer (RC) and to assess its prognostic value after resection.
METHODS: In this retrospective study, 46 patients with primary RC, who underwent multiparametric 18F-fluorodeoxyglucose (FDG) PET/MRI, followed by surgical resection without chemoradiotherapy, were included. Two readers reviewed T- and N- stage, mesorectal involvement, sphincter infiltration, tumor length, and distance from anal verge. In addition, diffusion-weighted imaging (DWI) and PET parameters were extracted from the multiparametric protocol and were compared to radiological staging as well as to the histopathological reference standard. Clinical and imaging follow-up was systematically assessed for tumor recurrence and death.
RESULTS: Locally advanced rectal cancers (LARC) exhibited significantly higher metabolic tumor volume (MTV, AUC 0.74 [95% CI 0.59-0.89], p = 0.004) and total lesion glycolysis (TLG, AUC 0.70 [95% CI 0.53-0.87], p = 0.022) compared to early tumors. T-stage was associated with MTV (AUC 0.70 [95% CI 0.54-0.85], p = 0.021), while N-stage was better assessed using anatomical MRI sequences (AUC 0.72 [95% CI 0.539-0.894], p = 0.032). In the multivariate regression analysis, depending on the model, both anatomical MRI sequences and MTV/TLG were capable of detecting LARC. Combining anatomical MRI stage and MTV/TLG led to a superior diagnostic performance for detecting LARC (AUC 0.81, [95% CI 0.68-0.94], p < 0.001). In the survival analysis, MTV was independently associated with overall survival (HR 1.05 [95% CI 1.01-1.10], p = 0.044).
CONCLUSION: Multiparametric PET-MRI can improve identification of locally advanced tumors and, hence, help in treatment stratification. It provides additional information on RC tumor biology and may have prognostic value.
© 2022. The Author(s).

Entities:  

Keywords:  MR; PET; PET/MRI; Rectal cancer; Staging

Year:  2022        PMID: 36063201     DOI: 10.1007/s00259-022-05936-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  25 in total

Review 1.  Hybrid imaging of the abdomen and pelvis.

Authors:  Krista Elise Suarez-Weiss; Alexander Herold; Debra Gervais; Edwin Palmer; Bárbara Amorim; Joseph D King; Li Weier; Tajmir Shahein; Hanna Bernstine; Liran Domachevsk; Lina Garcia Cañamaque; Ken Herrmann; Lale Umutlu; David Groshar; Onofrio A Catalano
Journal:  Radiologe       Date:  2020-11       Impact factor: 0.635

2.  Colorectal cancer statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-03-01       Impact factor: 508.702

3.  Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

Authors:  Renu R Bahadoer; Esmée A Dijkstra; Boudewijn van Etten; Corrie A M Marijnen; Hein Putter; Elma Meershoek-Klein Kranenbarg; Annet G H Roodvoets; Iris D Nagtegaal; Regina G H Beets-Tan; Lennart K Blomqvist; Tone Fokstuen; Albert J Ten Tije; Jaume Capdevila; Mathijs P Hendriks; Ibrahim Edhemovic; Andrés Cervantes; Per J Nilsson; Bengt Glimelius; Cornelis J H van de Velde; Geke A P Hospers
Journal:  Lancet Oncol       Date:  2020-12-07       Impact factor: 41.316

4.  Cancer statistics, 2022.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2022-01-12       Impact factor: 508.702

5.  Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.

Authors:  Morten Braendengen; Kjell M Tveit; Ake Berglund; Elke Birkemeyer; Gunilla Frykholm; Lars Påhlman; Johan N Wiig; Per Byström; Krzysztof Bujko; Bengt Glimelius
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

6.  Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Thierry Conroy; Jean-François Bosset; Pierre-Luc Etienne; Emmanuel Rio; Éric François; Nathalie Mesgouez-Nebout; Véronique Vendrely; Xavier Artignan; Olivier Bouché; Dany Gargot; Valérie Boige; Nathalie Bonichon-Lamichhane; Christophe Louvet; Clotilde Morand; Christelle de la Fouchardière; Najib Lamfichekh; Béata Juzyna; Claire Jouffroy-Zeller; Eric Rullier; Frédéric Marchal; Sophie Gourgou; Florence Castan; Christophe Borg
Journal:  Lancet Oncol       Date:  2021-04-13       Impact factor: 41.316

Review 7.  Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.

Authors:  Regina G H Beets-Tan; Doenja M J Lambregts; Monique Maas; Shandra Bipat; Brunella Barbaro; Luís Curvo-Semedo; Helen M Fenlon; Marc J Gollub; Sofia Gourtsoyianni; Steve Halligan; Christine Hoeffel; Seung Ho Kim; Andrea Laghi; Andrea Maier; Søren R Rafaelsen; Jaap Stoker; Stuart A Taylor; Michael R Torkzad; Lennart Blomqvist
Journal:  Eur Radiol       Date:  2017-10-17       Impact factor: 5.315

Review 8.  Imaging of colorectal cancer - the clue to individualized treatment.

Authors:  Dietmar Tamandl; Thomas Mang; Ahmed Ba-Ssalamah
Journal:  Innov Surg Sci       Date:  2018-03-13

9.  Estimating colorectal cancer treatment costs: a pragmatic approach exemplified by health insurance data from Germany.

Authors:  Ulrike Haug; Susanne Engel; Frank Verheyen; Roland Linder
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

10.  18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation.

Authors:  Felix G Gassert; Johannes Rübenthaler; Clemens C Cyran; Johann S Rink; Vincent Schwarze; Johanna Luitjens; Florian T Gassert; Marcus R Makowski; Stefan O Schoenberg; Marius E Mayerhoefer; Dietmar Tamandl; Matthias F Froelich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.